{"prompt": "['1', 'Protocol Synopsis', 'Sponsor:', 'Community Research Initiative of New England', '529 Main Street', 'Boston, MA 02129', 'Study Title:', 'Bridging Care to HCV Treatment Among Opioid Dependent Patients on', 'Buprenorphine/naloxone Maintenance Therapy: A Pilot Study of Treating HCV', 'with Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic', 'ClinicalTrials.gov', 'Identifier:', 'NCT03235154', 'Study Design:', 'This is an open label, single center, pilot study to evaluate the efficacy, safety', 'and tolerability of Epclusa treatment in na\u00efve and treatment-experienced', '(including treatment intolerant) subjects with chronic HCV infection genotypes', '1, 2, 3, 4, 5 and 6 in the context of a psychiatrist-staffed', 'buprenorphine/naloxone clinic.', 'Study Centers:', 'One study center in North America.', 'Objectives:', 'Primary Objective:', 'To assess the effectiveness, as measured by SVR12, of HCV treatment with', 'Epclusa administered by a psychiatrist/licensed buprenorphine/naloxone', 'provider during regularly scheduled visits to an outpatient addiction clinic for', 'buprenorphine/naloxone replacement therapy and mental healthcare.', 'Secondary Objectives: To assess the impact of HCV treatment on health-related quality of life among', 'subjects on buprenorphine/naloxone therapy.', 'To assess adherence to Epclusa therapy among subjects administered treatment', 'in the context of visits to an outpatient addiction clinic for', 'buprenorphine/naloxone replacement therapy and mental healthcare.', 'Exploratory Objective: To design and assess a curriculum and mentorship program to support', 'psychiatrists with managing HCV infection. For the purpose of this study, the', 'curriculum will be tailored to the management of HCV with Epclusa.', 'Number of Subjects:', '20', 'Target Population:', 'Approximately 20 subjects with chronic HCV infection genotypes 1, 2, 3, 4, 5 or 6', 'will be enrolled.', 'Study Product:', 'Epclusa (sofosbuvir/velpatasvir fixed dose combination tablets are pink,', 'diamond-shaped, film-coated tablets containing 400 mg of sofosbuvir and 100', 'mg of velpatasvir. Subjects will take one tablet daily with or without food.', 'Epclusa was approved by the FDA in 2016 for the treatment of adult patients', 'with chronic hepatitis C infection genotypes 1, 2, 3, 4, 5, 6. It is recommended as', 'first line therapy for treatment na\u00efve and pegylated-ribavirin-experienced adults', 'CRI 15-05 Protocol 13SEP2017', 'Page 5']['with chronic hepatitis C infection genotypes 1-6 (AASLD and IDSA HCV', 'Guidelines, October, 2016)', 'Duration of treatment: Subjects will be treated for 12 weeks.', 'Main Eligibility', 'Criteria:', 'Inclusion Criteria for clinical subjects:', 'Subjects must meet all of the following inclusion criteria to be eligible for', 'participation in this study.', '1. Willing and able to provide written informed consent', '2. Age 18 years', '3. Confirmation of chronic HCV infection as documented by a positive HCV', 'antibody test at least 6 months prior to the Baseline/Day 1 visit OR by', 'patient report of infection for at least 6 months prior to the baseline/day 1', 'visit AND positive HCV RNA test at screening', '4. HCV genotype 1, 2, 3, 4, 5 or 6', '5.', 'In stable remission from opioid use on buprenorphine/naloxone for at least', '12 weeks', '6. Within the following laboratory parameters as assessed at the screening', 'visit:', 'a.', 'HCV RNA quantifiable', 'b. Screening rhythm strip without bradycardia (heart rate > 60 or, if on', 'beta blocker, > 55 BPM)', 'c.', 'ALT 10 X ULN', 'd. AST < 10 X ULN', 'e.', 'Direct bilirubin < 1.5 x ULN', 'f.', 'Platelets > 60,000', 'g.', 'HbA1c < 13%', 'h.', 'Creatinine clearance 30 mL/min, as calculated by the Cockcroft-', 'Gault equation', 'i.', 'Albumin 3g/dL', 'j.', 'INR < 1.5 X ULN or on an anticoagulant regimen affecting INR', '7. Female subject is eligible to enter if it is confirmed that she is:', 'a.', 'Not pregnant or nursing', 'b.', 'Not of childbearing potential (i.e. s/p hysterectomy, oophorectomy', 'or has medically documented ovarian failure, or are postmenopausal', 'women > 50 years of age with cessation of menses for 12 months or', 'greater)', 'OR', 'Of childbearing potential with a negative serum pregnancy test', 'within 2 weeks of screening, a negative urine pregnancy test on Day', '1, and a commitment to either abstain from intercourse or', 'consistently use an acceptable method of birth control (Appendix 4)', 'CRI 15-05 Protocol 13SEP2017', 'Page 6']\n\n###\n\n", "completion": "END"}